Sir Isaac Newton, sepsis, SIRS, and CARS

[1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941

[2] PHYSIOLOGICAL STRESS AND CELLULAR ISCHEMIA - RELATIONSHIP TO IMMUNOSUPPRESSION AND SUSCEPTIBILITY TO SEPSIS [J]. CRITICAL CARE MEDICINE, 1991, 19 (05) : 613 - 618

[3] [Anonymous], 1991, J EXP MED, DOI DOI 10.1084/JEM.174.4.915

[4] THE PATHOGENESIS OF SEPSIS [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) : 457 - 469

[5] AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J]. CRITICAL CARE MEDICINE, 1992, 20 (06) : 864 - 874

[6] GRAM-POSITIVE ORGANISMS AND SEPSIS [J]. ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (01) : 26 - 34

[7] BROWDER W, 1990, ANN SURG, V211, P605

[8] BRUNET F, 1995, AM J RESP CRIT CARE, V151, P1269

[9] CHEADLE WG, 1989, IMMUNE CONSEQUENCES, P199

[10] PLATELET-ACTIVATING-FACTOR RECEPTOR ANTAGONIST BN-52021 IN THE TREATMENT OF SEVERE SEPSIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL-TRIAL [J]. CRITICAL CARE MEDICINE, 1994, 22 (11) : 1720 - 1728

[1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941

[2] PHYSIOLOGICAL STRESS AND CELLULAR ISCHEMIA - RELATIONSHIP TO IMMUNOSUPPRESSION AND SUSCEPTIBILITY TO SEPSIS [J]. CRITICAL CARE MEDICINE, 1991, 19 (05) : 613 - 618

[3] [Anonymous], 1991, J EXP MED, DOI DOI 10.1084/JEM.174.4.915

[4] THE PATHOGENESIS OF SEPSIS [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) : 457 - 469

[5] AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J]. CRITICAL CARE MEDICINE, 1992, 20 (06) : 864 - 874

[6] GRAM-POSITIVE ORGANISMS AND SEPSIS [J]. ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (01) : 26 - 34

[7] BROWDER W, 1990, ANN SURG, V211, P605

[8] BRUNET F, 1995, AM J RESP CRIT CARE, V151, P1269

[9] CHEADLE WG, 1989, IMMUNE CONSEQUENCES, P199

[10] PLATELET-ACTIVATING-FACTOR RECEPTOR ANTAGONIST BN-52021 IN THE TREATMENT OF SEVERE SEPSIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL-TRIAL [J]. CRITICAL CARE MEDICINE, 1994, 22 (11) : 1720 - 1728